Muhammad M Alam, MD
Hematology/Oncology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 26 years
- Graduated 2000
Offices
2 locations · Premier Cancer Care and Infusion Center · Camarena Health
Hospitals listed: Adventist Health Hanford · Clovis Community Medical Center · Community Regional Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Alam’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C144556 · Current
Licensed to practise in California · since 2016 · expires 2027-09-30 · Aga Khan University, Aga Khan Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health HanfordHanford, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.277, Oct 2024 – Sep 2025
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Hanford
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.277 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 614 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.38 to 1.15) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 190.5 (130.11 to 250.89) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.4 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 269 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.8 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.2 · 145 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,486 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,684 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 3,819 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.67 (0.36 to 4.98) · 613 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.32) · 154 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.65 (1.02 to 4.28) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.24 (0 to 16.19) · 160 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (0.67 to 9.03) · 147 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 1) · 3,186 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.418 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.574 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 38 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 14.5 · 302 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22 · 380 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 407 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 113 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10 to 17) · 896 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 228 cases | No different | Jan 2024 – Dec 2024 |
What patients said (947 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$1,118,792
Medicare paid this office $1,118,792 for 480 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 16 | $73,380 | None |
| Return visit (30+ min) | 249 | $55,552 | $97 |
| Injection, ferric derisomaltose, 10 mg | 28 | $50,652 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $41,004 | $94 |
| Long return visit (40+ min) | 123 | $38,258 | $139 |
See all 28 services
| Injection, denosumab, 1 mg | 16 | $73,380 | None |
| Return visit (30+ min) | 249 | $55,552 | $97 |
| Injection, ferric derisomaltose, 10 mg | 28 | $50,652 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $41,004 | $94 |
| Long return visit (40+ min) | 123 | $38,258 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 101 | $16,081 | $137 |
| New patient visit (60+ min) | 88 | $14,996 | $170 |
| New patient visit (45+ min) | 91 | $12,132 | $133 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $11,146 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $6,437 | $63 |
| Injection of drug or substance under skin or into muscle | 81 | $4,101 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 17 | $3,053 | $24 |
| Infusion into a vein for hydration, each additional hour | 45 | $2,918 | $10 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $2,897 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 38 | $2,716 | $52 |
| Short return visit (20+ min) | 17 | $1,408 | $74 |
| New patient visit (30+ min) | 11 | $1,012 | $92 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $917 | $28 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 11 | $419 | $8 |
| Injection of additional new drug or substance into vein | 13 | $391 | $13 |
| Blood test, comprehensive group of blood chemicals | 11 | $383 | $10 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 13 | $365 | $24 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 40 | $153 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $81 | None |
| Infusion, normal saline solution, 250 cc | 40 | $54 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 20 | $52 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $33 | None |
| Unclassified drugs | 13 | $14 | None |
Who their Medicare patients are
480 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 65% · Also on Medicaid 26% · Health risk score 1.83. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 50% · Chronic kidney disease 41% · Diabetes 40% · Coronary heart disease 34% · Heart failure 25% · Atrial fibrillation 24% · Depression 21% · COPD 17% · Stroke 11% · Dementia 8%.
The office billed $3,494,160, Medicare allowed $1,410,907 and paid $1,118,792; for 66,943 services of 117 kinds; $887,333 of it was for drugs given in the office and $231,459 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 480 | 66,943 | 75 | 1.83 | $3,494,160 | $1,118,792 |
| 2023 | 563 | 2,704 | 74 | 2.08 | $681,099 | $204,166 |
| 2022 | 570 | 2,836 | 74 | 2.07 | $682,709 | $230,802 |
| 2021 | 476 | 2,074 | 73 | 1.99 | $497,778 | $179,314 |
| 2020 | 475 | 2,500 | 73 | 2.18 | $549,614 | $167,240 |
| 2019 | 435 | 2,928 | 73 | 2.03 | $646,964 | $239,794 |
| 2018 | 273 | 1,201 | 73 | 1.97 | $294,872 | $107,392 |
| 2017 | 196 | 744 | 73 | 1.72 | $178,141 | $76,469 |
| 2016 | 245 | 26,430 | 74 | 2.01 | $269,976 | $116,581 |
| 2015 | 203 | 4,700 | 74 | 1.61 | $260,043 | $112,368 |
| 2014 | 117 | 33,075 | 74 | 1.78 | $210,201 | $89,249 |
| 2013 | 38 | 198 | 74 | 1.69 | $32,249 | $15,654 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 404 | $88,425 | $94 |
| Long return visit (40+ min) | 165 | $45,917 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 88 | $28,799 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $9,796 | $138 |
| New patient visit (60+ min) | 57 | $8,893 | $156 |
| Telephone medical discussion with physician, 11-20 minutes | 74 | $5,242 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,556 | $60 |
| Injection of drug or substance under skin or into muscle | 105 | $3,811 | $11 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,103 | $100 |
| Short return visit (20+ min) | 23 | $1,795 | $69 |
| New patient visit (45+ min) | 13 | $1,702 | $131 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 108 | $411 | None |
2022: 15 services
| Return visit (30+ min) | 411 | $86,169 | $95 |
| Long return visit (40+ min) | 187 | $76,884 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $19,331 | $82 |
| New patient visit (60+ min) | 62 | $10,603 | $171 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,481 | $157 |
| Telephone medical discussion with physician, 21-30 minutes | 45 | $4,740 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 54 | $4,543 | $74 |
| New patient visit (45+ min) | 33 | $3,937 | $119 |
| Injection of drug or substance under skin or into muscle | 89 | $3,674 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 40 | $2,974 | $65 |
| Telephone medical discussion with physician, 5-10 minutes | 62 | $2,873 | $38 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,654 | $54 |
| Short return visit (20+ min) | 28 | $1,750 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $439 | $27 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 89 | $402 | None |
2021: 16 services
| Long return visit (40+ min) | 143 | $63,497 | $150 |
| Return visit (30+ min) | 264 | $55,981 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $17,512 | $85 |
| New patient visit (60+ min) | 60 | $10,633 | $177 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,613 | $165 |
| New patient visit (45+ min) | 38 | $5,255 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,788 | $59 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 30 | $2,732 | $83 |
| Telephone medical discussion with physician, 5-10 minutes | 53 | $2,526 | $46 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 153 | $2,047 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,728 | $96 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,485 | $74 |
| Injection of drug or substance under skin or into muscle | 38 | $1,218 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $1,089 | $18 |
| Short return visit (20+ min) | 11 | $730 | $66 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 54 | $261 | None |
2020: 14 services
| Return visit (30+ min) | 292 | $66,046 | $81 |
| Long return visit (40+ min) | 135 | $34,962 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $14,358 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $12,135 | $85 |
| New patient visit (60+ min) | 50 | $8,155 | $163 |
| New patient visit (45+ min) | 48 | $5,977 | $125 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 36 | $5,645 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,498 | $149 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $5,265 | $101 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 53 | $3,391 | $17 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 171 | $2,760 | $12 |
| Short return visit (20+ min) | 25 | $1,039 | $37 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 79 | $362 | None |
| Injection of drug or substance under skin or into muscle | 20 | $192 | $8 |
2019: 13 services
| Return visit (30+ min) | 278 | $79,372 | $86 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 69 | $64,445 | $157 |
| Long return visit (40+ min) | 119 | $30,324 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $13,262 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $10,420 | $85 |
| New patient visit (60+ min) | 60 | $9,433 | $157 |
| New patient visit (45+ min) | 64 | $8,346 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 68 | $7,486 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,466 | $161 |
| Short return visit (20+ min) | 71 | $4,858 | $56 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 47 | $3,444 | $19 |
| Injection of drug or substance under skin or into muscle | 60 | $1,344 | $12 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 85 | $480 | None |
2018: 11 services
| Return visit (30+ min) | 145 | $39,906 | $85 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 30 | $27,283 | $157 |
| Short return visit (20+ min) | 156 | $13,453 | $54 |
| New patient visit (45+ min) | 78 | $9,948 | $128 |
| New patient visit (60+ min) | 23 | $3,862 | $168 |
| Long return visit (40+ min) | 25 | $3,448 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,950 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,602 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,097 | $78 |
| Injection of drug or substance under skin or into muscle | 27 | $790 | $17 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 27 | $71 | None |
2017: 9 services
| Return visit (30+ min) | 90 | $21,386 | $87 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 16 | $11,133 | $157 |
| New patient visit (45+ min) | 80 | $10,537 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $8,805 | $160 |
| Short return visit (20+ min) | 79 | $6,557 | $58 |
| New patient visit (60+ min) | 32 | $5,385 | $168 |
| Long return visit (40+ min) | 24 | $4,404 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,877 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,536 | $56 |
2016: 7 services
| Return visit (30+ min) | 143 | $34,858 | $73 |
| Short return visit (20+ min) | 213 | $27,528 | $53 |
| Long return visit (40+ min) | 52 | $15,436 | $98 |
| Biopsy of bone marrow | 20 | $2,591 | $118 |
| New patient visit (45+ min) | 22 | $2,565 | $117 |
| New patient visit (60+ min) | 12 | $1,686 | $140 |
| Injection of drug or substance under skin or into muscle | 13 | $1,478 | $18 |
2015: 8 services
| Return visit (30+ min) | 180 | $42,655 | $75 |
| Long return visit (40+ min) | 106 | $37,047 | $101 |
| Injection, tbo-filgrastim, 5 micrograms | 11 | $7,492 | None |
| New patient visit (60+ min) | 38 | $5,686 | $150 |
| Short return visit (20+ min) | 30 | $1,917 | $50 |
| Biopsy of bone marrow | 14 | $1,740 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,448 | $76 |
| Injection of drug or substance under skin or into muscle | 19 | $1,126 | $18 |
2014: 5 services
| Long return visit (40+ min) | 73 | $26,706 | $109 |
| Return visit (30+ min) | 90 | $19,051 | $78 |
| New patient visit (60+ min) | 50 | $7,524 | $150 |
| Biopsy of bone marrow | 13 | $1,506 | $116 |
| Short return visit (20+ min) | 24 | $1,312 | $52 |
2013: 3 services
| Return visit (30+ min) | 20 | $3,989 | $81 |
| New patient visit (60+ min) | 15 | $2,348 | $157 |
| Short return visit (20+ min) | 22 | $1,349 | $54 |
Medicaid work
$2,017 in 2024
Medicaid paid $2,017 for 387 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 131 | $1,304 |
| Return visit (30+ min) | 167 | $602 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 89 | $110 |
| 2024 | 387 | 3 | 25 | $2,017 |
| 2023 | 2,268 | 16 | 70 | $7,405 |
| 2022 | 3,081 | 20 | 63 | $10,613 |
| 2021 | 970 | 13 | 29 | $7,216 |
| 2020 | 120 | 2 | 16 | $499 |
| 2019 | 54 | 1 | 14 | $0 |
| 2018 | 366 | 3 | 26 | $1,445 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 627 | $2,120 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 119 | $1,418 |
| COMPREHENSIVE METABOLIC PANEL | 236 | $724 |
| Long return visit (40+ min) | 197 | $711 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 36 | $657 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 237 | $529 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 261 | $417 |
| Measurement of transferrin | 55 | $188 |
| Measurement of folic acid in serum | 42 | $170 |
| Measurement of ferritin | 42 | $151 |
| Measurement of iron | 55 | $95 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 243 | $93 |
2022
| Return visit (30+ min) | 549 | $2,185 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 90 | $2,106 |
| Long return visit (40+ min) | 340 | $1,860 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 112 | $1,562 |
| COMPREHENSIVE METABOLIC PANEL | 428 | $716 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 430 | $533 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $398 |
| Measurement of folic acid in serum | 69 | $247 |
| Measurement of transferrin | 69 | $201 |
| Measurement of ferritin | 57 | $148 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 82 | $129 |
| VITAMIN B-12 | 43 | $103 |
2021
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 75 | $2,288 |
| COMPREHENSIVE METABOLIC PANEL | 279 | $1,416 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 78 | $1,400 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 264 | $982 |
| Long return visit (40+ min) | 35 | $443 |
| Measurement of ferritin | 17 | $124 |
| Infusion, normal saline solution, 250 cc | 67 | $122 |
| Measurement of folic acid in serum | 16 | $117 |
| Measurement of transferrin | 16 | $98 |
| Return visit (30+ min) | 53 | $96 |
| Infusion, normal saline solution , 1000 cc | 38 | $50 |
| Measurement of iron | 16 | $50 |
2020
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 17 | $499 |
| Return visit (30+ min) | 103 | $0 |
2019
| Return visit (30+ min) | 54 | $0 |
2018
| Return visit (30+ min) | 266 | $1,156 |
| New patient visit (45+ min) | 13 | $217 |
| Short return visit (20+ min) | 87 | $72 |
Drugs they prescribed that Part D paid
$2,986,066
Pharmacies billed $2,986,066 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (70 of 1,345) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 20% of their opioid prescriptions.
1,009 generic and 336 brand-name prescriptions · $2,986,066 in drug cost · 69 antibiotic prescriptions to 38 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zejula | 24 | $673,802 | $28,075 |
| Revlimid | 13 | $225,967 | $17,382 |
| Welireg | 12 | $225,070 | $18,756 |
| Xtandi | 18 | $206,502 | $11,472 |
| Sprycel | 11 | $193,119 | $17,556 |
See all 39 drugs
| Zejula | 24 | $673,802 | $28,075 |
| Revlimid | 13 | $225,967 | $17,382 |
| Welireg | 12 | $225,070 | $18,756 |
| Xtandi | 18 | $206,502 | $11,472 |
| Sprycel | 11 | $193,119 | $17,556 |
| Ibrance | 12 | $189,830 | $15,819 |
| Lenalidomide | 13 | $167,957 | $12,920 |
| Eliquis | 94 | $63,233 | $673 |
| Xarelto | 26 | $19,498 | $750 |
| Clinisol | 55 | $18,913 | $344 |
| Abiraterone Acetate | 14 | $11,954 | $854 |
| Creon | 14 | $6,137 | $438 |
| Megestrol Acetate | 24 | $2,269 | $95 |
| Ondansetron Odt | 64 | $2,104 | $33 |
| Anastrozole | 65 | $1,599 | $25 |
| Dexamethasone | 75 | $1,323 | $18 |
| Hydrocodone-Acetaminophen | 31 | $1,019 | $33 |
| Acyclovir | 26 | $817 | $31 |
| Potassium Chloride | 26 | $659 | $25 |
| Hydroxyurea | 33 | $588 | $18 |
| Prochlorperazine Maleate | 34 | $471 | $14 |
| Oxycodone-Acetaminophen | 17 | $465 | $27 |
| Pantoprazole | 32 | $432 | $13 |
| Gabapentin | 37 | $327 | $9 |
| Omeprazole | 17 | $319 | $19 |
| Prednisone | 33 | $281 | $9 |
| Levothyroxine | 27 | $260 | $10 |
| Escitalopram | 13 | $165 | $13 |
| Folic Acid | 18 | $158 | $9 |
| Metoclopramide | 18 | $149 | $8 |
| Levofloxacin | 22 | $119 | $5 |
| Allopurinol | 14 | $92 | $7 |
| Novolin R | 14 | $70 | $5 |
| Mirtazapine | 12 | $67 | $6 |
| Alprazolam | 12 | $59 | $5 |
| Furosemide | 22 | $53 | $2 |
| Ondansetron | 15 | $51 | $3 |
| Amlodipine Besylate | 11 | $45 | $4 |
| Sulfamethoxazole-Trimethoprim | 14 | $12 | $1 |
Year by year
| 2024 | 1,345 | 255 | 5% (70) | 25% | $2,986,066 |
| 2023 | 2,163 | 298 | 8% (175) | None | $3,149,595 |
| 2022 | 2,911 | 312 | 6% (170) | 22% | $3,579,661 |
| 2021 | 2,445 | 276 | 8% (200) | None | $3,084,415 |
| 2020 | 1,998 | 250 | 7% (146) | None | $2,379,342 |
| 2019 | 1,828 | 197 | 11% (203) | None | $1,449,724 |
| 2018 | 1,191 | 143 | 12% (144) | None | $740,474 |
| 2017 | 658 | 117 | 15% (96) | 16% | $321,242 |
| 2016 | 913 | 155 | 9% (83) | 17% | $690,650 |
| 2015 | 1,279 | 168 | 8% (107) | None | $948,810 |
| 2014 | 568 | 104 | 14% (79) | None | $446,764 |
| 2013 | 72 | 18 | None | None | $10,637 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 51 drugs
| Imbruvica | 29 | $466,766 | $16,095 |
| Revlimid | 25 | $460,223 | $18,409 |
| Inlyta | 26 | $378,794 | $14,569 |
| Zejula | 11 | $237,350 | $21,577 |
| Lonsurf | 15 | $149,772 | $9,985 |
| Eliquis | 180 | $120,204 | $668 |
| Abiraterone Acetate | 16 | $45,556 | $2,847 |
| Xarelto | 27 | $26,285 | $974 |
| Creon | 12 | $20,143 | $1,679 |
| Hydroxyurea | 59 | $1,822 | $31 |
| Anastrozole | 37 | $1,794 | $48 |
| Hydrocodone-Acetaminophen | 57 | $1,715 | $30 |
| Potassium Chloride | 108 | $1,667 | $15 |
| Dexamethasone | 125 | $1,574 | $13 |
| Megestrol Acetate | 14 | $1,506 | $108 |
| Ondansetron Odt | 45 | $1,108 | $25 |
| Oxycodone | 35 | $1,059 | $30 |
| Pantoprazole | 53 | $999 | $19 |
| Prochlorperazine Maleate | 68 | $853 | $13 |
| Ondansetron | 107 | $830 | $8 |
| Doxycycline Monohydrate | 18 | $773 | $43 |
| Prednisone | 111 | $752 | $7 |
| Oxycodone-Acetaminophen | 18 | $656 | $36 |
| Levothyroxine | 60 | $619 | $10 |
| Tamsulosin | 14 | $598 | $43 |
| Escitalopram | 28 | $541 | $19 |
| Sodium Chloride | 15 | $527 | $35 |
| Amlodipine Besylate | 26 | $495 | $19 |
| Gabapentin | 48 | $478 | $10 |
| Zolpidem | 35 | $433 | $12 |
| Acyclovir | 35 | $430 | $12 |
| Diphenoxylate-Atropine | 12 | $402 | $33 |
| Albuterol Sulfate Hfa | 11 | $388 | $35 |
| Lidocaine-Prilocaine | 24 | $346 | $14 |
| Omeprazole | 29 | $335 | $12 |
| Klor-Con 10 | 12 | $311 | $26 |
| Allopurinol | 27 | $292 | $11 |
| Morphine Sulfate Er | 12 | $284 | $24 |
| Levofloxacin | 20 | $274 | $14 |
| Loperamide | 18 | $257 | $14 |
| Tramadol | 33 | $230 | $7 |
| Venlafaxine Hcl Er | 15 | $207 | $14 |
| Sulfamethoxazole-Trimethoprim | 22 | $187 | $8 |
| Furosemide | 26 | $156 | $6 |
| Ciprofloxacin | 23 | $151 | $7 |
| Mirtazapine | 13 | $118 | $9 |
| Alprazolam | 18 | $116 | $6 |
| Cephalexin | 17 | $107 | $6 |
| Metronidazole | 11 | $78 | $7 |
| Metoclopramide | 12 | $77 | $6 |
| Folic Acid | 21 | $64 | $3 |
2022: 62 drugs
| Revlimid | 66 | $1,276,684 | $19,344 |
| Lenvima | 13 | $284,181 | $21,860 |
| Zejula | 16 | $277,980 | $17,374 |
| Inlyta | 21 | $274,143 | $13,054 |
| Imbruvica | 14 | $216,774 | $15,484 |
| Verzenio | 12 | $187,979 | $15,665 |
| Xtandi | 21 | $153,441 | $7,307 |
| Eliquis | 180 | $122,974 | $683 |
| Abiraterone Acetate | 21 | $63,318 | $3,015 |
| Creon | 42 | $60,051 | $1,430 |
| Xarelto | 19 | $17,952 | $945 |
| Clinisol | 43 | $15,097 | $351 |
| Megestrol Acetate | 42 | $6,068 | $144 |
| Dronabinol | 12 | $3,441 | $287 |
| Potassium Chloride | 182 | $3,170 | $17 |
| Ondansetron | 186 | $2,864 | $15 |
| Dexamethasone | 190 | $2,560 | $13 |
| Hydrocodone-Acetaminophen | 69 | $2,347 | $34 |
| Prochlorperazine Maleate | 165 | $2,141 | $13 |
| Ondansetron Odt | 48 | $1,989 | $41 |
| Hydroxyurea | 49 | $1,620 | $33 |
| Sodium Chloride | 44 | $1,328 | $30 |
| Gabapentin | 70 | $1,271 | $18 |
| Oxycodone | 33 | $1,108 | $34 |
| Oxycodone-Acetaminophen | 20 | $1,051 | $53 |
| Prednisone | 144 | $966 | $7 |
| Lidocaine-Prilocaine | 35 | $929 | $27 |
| Levothyroxine | 52 | $865 | $17 |
| Pantoprazole | 44 | $794 | $18 |
| Diphenoxylate-Atropine | 17 | $742 | $44 |
| Ventolin Hfa | 11 | $703 | $64 |
| Morphine Sulfate Er | 16 | $699 | $44 |
| Baclofen | 15 | $629 | $42 |
| Zolpidem | 43 | $543 | $13 |
| Loperamide | 28 | $519 | $19 |
| Acyclovir | 23 | $445 | $19 |
| Levofloxacin | 43 | $439 | $10 |
| Klor-Con 10 | 28 | $417 | $15 |
| Doxycycline Monohydrate | 27 | $368 | $14 |
| Novolin R | 20 | $325 | $16 |
| Anastrozole | 19 | $320 | $17 |
| Venlafaxine Hcl Er | 16 | $276 | $17 |
| Omeprazole | 24 | $247 | $10 |
| Sulfamethoxazole-Trimethoprim | 30 | $223 | $7 |
| Escitalopram | 32 | $222 | $7 |
| Amlodipine Besylate | 19 | $209 | $11 |
| Allopurinol | 30 | $202 | $7 |
| Furosemide | 43 | $190 | $4 |
| Tamsulosin | 16 | $189 | $12 |
| Metronidazole | 13 | $171 | $13 |
| Dexamethasone Sodium Phosphate | 18 | $130 | $7 |
| Mirtazapine | 12 | $111 | $9 |
| Tramadol | 18 | $110 | $6 |
| Ciprofloxacin | 20 | $102 | $5 |
| Alprazolam | 21 | $98 | $5 |
| Cephalexin | 16 | $97 | $6 |
| Easy Touch Alcohol Prep Pads | 21 | $94 | $4 |
| Azithromycin | 17 | $92 | $5 |
| Warfarin | 24 | $92 | $4 |
| Folic Acid | 18 | $78 | $4 |
| Euthyrox | 12 | $42 | $4 |
| Lisinopril | 18 | $41 | $2 |
2021: 52 drugs
| Revlimid | 47 | $854,655 | $18,184 |
| Pomalyst | 27 | $542,690 | $20,100 |
| Lenvima | 13 | $264,475 | $20,344 |
| Xtandi | 22 | $261,310 | $11,878 |
| Zejula | 12 | $193,177 | $16,098 |
| Imbruvica | 13 | $191,176 | $14,706 |
| Eliquis | 146 | $87,963 | $602 |
| Creon | 29 | $35,403 | $1,221 |
| Xarelto | 23 | $15,358 | $668 |
| Abiraterone Acetate | 12 | $7,150 | $596 |
| Enoxaparin | 14 | $6,977 | $498 |
| Dexamethasone | 169 | $3,036 | $18 |
| Potassium Chloride | 127 | $2,860 | $23 |
| Megestrol Acetate | 31 | $2,179 | $70 |
| Hydrocodone-Acetaminophen | 77 | $2,024 | $26 |
| Hydroxyurea | 37 | $1,903 | $51 |
| Ondansetron Odt | 47 | $1,674 | $36 |
| Prochlorperazine Maleate | 124 | $1,606 | $13 |
| Ondansetron | 128 | $1,446 | $11 |
| Prednisone | 125 | $993 | $8 |
| Diphenoxylate-Atropine | 15 | $853 | $57 |
| Morphine Sulfate Er | 25 | $783 | $31 |
| Levothyroxine | 44 | $782 | $18 |
| Levofloxacin | 41 | $733 | $18 |
| Oxycodone | 37 | $621 | $17 |
| Anastrozole | 19 | $607 | $32 |
| Acyclovir | 37 | $550 | $15 |
| Sodium Chloride | 29 | $547 | $19 |
| Pantoprazole | 36 | $539 | $15 |
| Gabapentin | 48 | $465 | $10 |
| Baclofen | 12 | $421 | $35 |
| Lidocaine-Prilocaine | 23 | $416 | $18 |
| Omeprazole | 48 | $390 | $8 |
| Doxycycline Monohydrate | 24 | $328 | $14 |
| Tamsulosin | 17 | $319 | $19 |
| Metronidazole | 22 | $312 | $14 |
| Loperamide | 15 | $303 | $20 |
| Sulfamethoxazole-Trimethoprim | 46 | $253 | $6 |
| Zolpidem | 29 | $224 | $8 |
| Klor-Con 10 | 18 | $216 | $12 |
| Tramadol | 34 | $186 | $5 |
| Lidocaine Hcl Viscous | 15 | $165 | $11 |
| Furosemide | 29 | $143 | $5 |
| Escitalopram | 31 | $132 | $4 |
| Losartan | 24 | $121 | $5 |
| Ciprofloxacin | 22 | $109 | $5 |
| Alprazolam | 15 | $89 | $6 |
| Euthyrox | 12 | $78 | $7 |
| Lisinopril | 22 | $75 | $3 |
| Citalopram Hbr | 16 | $56 | $4 |
| Amlodipine Besylate | 16 | $51 | $3 |
| Folic Acid | 12 | $44 | $4 |
2020: 46 drugs
| Revlimid | 48 | $817,463 | $17,030 |
| Pomalyst | 25 | $454,778 | $18,191 |
| Imbruvica | 12 | $155,724 | $12,977 |
| Ninlaro | 11 | $120,298 | $10,936 |
| Eliquis | 126 | $72,550 | $576 |
| Creon | 32 | $38,951 | $1,217 |
| Xarelto | 51 | $27,728 | $544 |
| Fondaparinux | 11 | $26,370 | $2,397 |
| Potassium Chloride | 109 | $3,919 | $36 |
| Dexamethasone | 136 | $3,159 | $23 |
| Morphine Sulfate Er | 36 | $1,702 | $47 |
| Hydroxyurea | 35 | $1,529 | $44 |
| Prochlorperazine Maleate | 106 | $1,432 | $14 |
| Megestrol Acetate | 19 | $1,164 | $61 |
| Ondansetron | 115 | $1,015 | $9 |
| Hydrocodone-Acetaminophen | 44 | $1,010 | $23 |
| Morphine Sulfate | 14 | $776 | $55 |
| Lidocaine Hcl Viscous | 28 | $749 | $27 |
| Prednisone | 113 | $746 | $7 |
| Pantoprazole | 68 | $723 | $11 |
| Acyclovir | 43 | $711 | $17 |
| Ondansetron Odt | 19 | $572 | $30 |
| Anastrozole | 17 | $563 | $33 |
| Levofloxacin | 33 | $552 | $17 |
| Levothyroxine | 37 | $550 | $15 |
| Oxycodone | 21 | $544 | $26 |
| Loperamide | 22 | $451 | $21 |
| Tamsulosin | 15 | $378 | $25 |
| Gabapentin | 32 | $299 | $9 |
| Sulfamethoxazole-Trimethoprim | 23 | $299 | $13 |
| Omeprazole | 31 | $285 | $9 |
| Metronidazole | 17 | $230 | $14 |
| Fluoxetine | 17 | $155 | $9 |
| Metoclopramide | 16 | $150 | $9 |
| Lorazepam | 18 | $139 | $8 |
| Ciprofloxacin | 19 | $132 | $7 |
| Furosemide | 42 | $128 | $3 |
| Amlodipine Besylate | 16 | $124 | $8 |
| Allopurinol | 14 | $115 | $8 |
| Azithromycin | 14 | $98 | $7 |
| Zolpidem | 13 | $84 | $6 |
| Cephalexin | 15 | $74 | $5 |
| Alprazolam | 13 | $73 | $6 |
| Citalopram Hbr | 15 | $64 | $4 |
| Tramadol | 16 | $56 | $3 |
| Lisinopril | 12 | $43 | $4 |
2019: 37 drugs
| Revlimid | 26 | $409,133 | $15,736 |
| Pomalyst | 15 | $259,889 | $17,326 |
| Eliquis | 105 | $53,767 | $512 |
| Creon | 29 | $29,714 | $1,025 |
| Xarelto | 39 | $18,219 | $467 |
| Potassium Chloride | 81 | $2,930 | $36 |
| Morphine Sulfate Er | 64 | $2,224 | $35 |
| Minocycline | 15 | $2,036 | $136 |
| Dexamethasone | 97 | $1,925 | $20 |
| Megestrol Acetate | 35 | $1,686 | $48 |
| Hydrocodone-Acetaminophen | 51 | $1,577 | $31 |
| Prochlorperazine Maleate | 121 | $1,219 | $10 |
| Ondansetron | 141 | $1,172 | $8 |
| Morphine Sulfate | 16 | $1,126 | $70 |
| Gabapentin | 39 | $805 | $21 |
| Hydroxyurea | 22 | $710 | $32 |
| Ondansetron Odt | 34 | $684 | $20 |
| Oxycodone | 31 | $632 | $20 |
| Prednisone | 100 | $591 | $6 |
| Pantoprazole | 54 | $567 | $11 |
| Levofloxacin | 37 | $567 | $15 |
| Anastrozole | 13 | $452 | $35 |
| Acyclovir | 38 | $366 | $10 |
| Levothyroxine | 21 | $289 | $14 |
| Tamsulosin | 14 | $237 | $17 |
| Lidocaine-Prilocaine | 11 | $204 | $19 |
| Furosemide | 37 | $180 | $5 |
| Zolpidem | 20 | $161 | $8 |
| Allopurinol | 15 | $147 | $10 |
| Loperamide | 13 | $145 | $11 |
| Metoclopramide | 43 | $140 | $3 |
| Tramadol | 25 | $133 | $5 |
| Alprazolam | 26 | $117 | $4 |
| Sulfamethoxazole-Trimethoprim | 27 | $105 | $4 |
| Azithromycin | 12 | $97 | $8 |
| Escitalopram | 14 | $90 | $6 |
| Citalopram Hbr | 12 | $67 | $6 |
2018: 31 drugs
| Revlimid | 17 | $220,351 | $12,962 |
| Xtandi | 15 | $172,221 | $11,481 |
| Gilotrif | 13 | $113,141 | $8,703 |
| Eliquis | 61 | $28,139 | $461 |
| Xarelto | 30 | $12,557 | $419 |
| Creon | 16 | $5,599 | $350 |
| Dronabinol | 19 | $3,153 | $166 |
| Potassium Chloride | 46 | $1,786 | $39 |
| Hydrocodone-Acetaminophen | 66 | $1,362 | $21 |
| Hydroxyurea | 44 | $1,337 | $30 |
| Minocycline | 16 | $1,253 | $78 |
| Dexamethasone | 56 | $948 | $17 |
| Megestrol Acetate | 17 | $912 | $54 |
| Morphine Sulfate Er | 27 | $911 | $34 |
| Ondansetron | 82 | $689 | $8 |
| Prochlorperazine Maleate | 87 | $547 | $6 |
| Diphenoxylate-Atropine | 20 | $500 | $25 |
| Gabapentin | 27 | $402 | $15 |
| Oxycodone-Acetaminophen | 12 | $395 | $33 |
| Bicalutamide | 15 | $352 | $23 |
| Metoclopramide | 85 | $297 | $3 |
| Pantoprazole | 43 | $287 | $7 |
| Acyclovir | 19 | $190 | $10 |
| Levofloxacin | 16 | $181 | $11 |
| Ondansetron Odt | 17 | $176 | $10 |
| Sodium Chloride | 18 | $164 | $9 |
| Citalopram Hbr | 15 | $163 | $11 |
| Levothyroxine | 17 | $154 | $9 |
| Prednisone | 11 | $69 | $6 |
| Tramadol | 13 | $56 | $4 |
| Alprazolam | 13 | $33 | $3 |
2017: 16 drugs
| Eliquis | 23 | $9,098 | $396 |
| Morphine Sulfate Er | 25 | $1,150 | $46 |
| Tamoxifen Citrate | 16 | $594 | $37 |
| Hydrocodone-Acetaminophen | 37 | $513 | $14 |
| Dexamethasone | 32 | $481 | $15 |
| Anastrozole | 33 | $456 | $14 |
| Levofloxacin | 21 | $326 | $16 |
| Nystatin | 15 | $317 | $21 |
| Ondansetron | 21 | $288 | $14 |
| Prednisone | 42 | $252 | $6 |
| Prochlorperazine Maleate | 33 | $240 | $7 |
| Ondansetron Odt | 17 | $186 | $11 |
| Bicalutamide | 11 | $161 | $15 |
| Metoclopramide | 15 | $57 | $4 |
| Citalopram Hbr | 11 | $52 | $5 |
| Alprazolam | 13 | $29 | $2 |
2016: 26 drugs
| Xtandi | 37 | $251,124 | $6,787 |
| Revlimid | 12 | $137,591 | $11,466 |
| Exemestane | 23 | $6,611 | $287 |
| Anastrozole | 135 | $3,603 | $27 |
| Nexium | 11 | $2,818 | $256 |
| Anagrelide | 19 | $1,756 | $92 |
| Hydroxyurea | 35 | $1,733 | $50 |
| Morphine Sulfate Er | 15 | $1,079 | $72 |
| Potassium Chloride | 26 | $610 | $23 |
| Ondansetron | 18 | $483 | $27 |
| Tamoxifen Citrate | 12 | $475 | $40 |
| Bicalutamide | 11 | $385 | $35 |
| Levofloxacin | 15 | $334 | $22 |
| Letrozole | 27 | $269 | $10 |
| Klor-Con M20 | 15 | $256 | $17 |
| Warfarin | 25 | $239 | $10 |
| Gabapentin | 28 | $232 | $8 |
| Dexamethasone | 24 | $205 | $9 |
| Hydrocodone-Acetaminophen | 30 | $181 | $6 |
| Acyclovir | 22 | $175 | $8 |
| Levothyroxine | 13 | $163 | $13 |
| Escitalopram | 11 | $95 | $9 |
| Prednisone | 22 | $82 | $4 |
| Lisinopril | 16 | $52 | $3 |
| Alprazolam | 11 | $25 | $2 |
| Lorazepam | 12 | $23 | $2 |
2015: 40 drugs
| Revlimid | 26 | $266,410 | $10,247 |
| Xtandi | 40 | $255,266 | $6,382 |
| Pomalyst | 11 | $128,341 | $11,667 |
| Imbruvica | 11 | $101,793 | $9,254 |
| Exemestane | 24 | $11,077 | $462 |
| Anastrozole | 123 | $3,600 | $29 |
| Ondansetron | 34 | $1,379 | $41 |
| Anagrelide | 15 | $1,303 | $87 |
| Hydroxyurea | 26 | $1,239 | $48 |
| Venlafaxine Hcl Er | 14 | $1,003 | $72 |
| Tamoxifen Citrate | 22 | $994 | $45 |
| Potassium Chloride | 38 | $944 | $25 |
| Klor-Con M20 | 25 | $839 | $34 |
| Morphine Sulfate Er | 13 | $748 | $58 |
| Levofloxacin | 34 | $583 | $17 |
| Dexamethasone | 72 | $521 | $7 |
| Warfarin | 44 | $517 | $12 |
| Nystatin | 15 | $493 | $33 |
| Megestrol Acetate | 12 | $427 | $36 |
| Letrozole | 31 | $383 | $12 |
| Prednisone | 56 | $335 | $6 |
| Hydrocodone-Acetaminophen | 33 | $314 | $10 |
| Oxycodone-Acetaminophen | 18 | $259 | $14 |
| Oxycodone | 17 | $243 | $14 |
| Escitalopram | 13 | $235 | $18 |
| Allopurinol | 20 | $225 | $11 |
| Venlafaxine | 16 | $204 | $13 |
| Prochlorperazine Maleate | 23 | $191 | $8 |
| Citalopram Hbr | 29 | $191 | $7 |
| Tramadol | 22 | $178 | $8 |
| Acyclovir | 12 | $176 | $15 |
| Ranitidine | 17 | $128 | $8 |
| Omeprazole | 22 | $127 | $6 |
| Ciprofloxacin | 14 | $100 | $7 |
| Clindamycin | 13 | $97 | $7 |
| Lisinopril | 16 | $83 | $5 |
| Alprazolam | 16 | $56 | $3 |
| Amlodipine Besylate | 14 | $46 | $3 |
| Lorazepam | 13 | $36 | $3 |
| Furosemide | 16 | $35 | $2 |
2014: 16 drugs
| Zytiga | 15 | $113,207 | $7,547 |
| Exemestane | 17 | $5,885 | $346 |
| Morphine Sulfate Er | 19 | $1,266 | $67 |
| Anastrozole | 36 | $949 | $26 |
| Ondansetron | 25 | $586 | $23 |
| Mometasone Furoate | 11 | $429 | $39 |
| Oxycodone | 18 | $422 | $23 |
| Klor-Con M20 | 16 | $291 | $18 |
| Hydrocodone-Acetaminophen | 24 | $252 | $10 |
| Dexamethasone | 33 | $221 | $7 |
| Levofloxacin | 12 | $209 | $17 |
| Prednisone | 19 | $177 | $9 |
| Warfarin | 13 | $137 | $11 |
| Allopurinol | 19 | $128 | $7 |
| Omeprazole | 12 | $84 | $7 |
| Citalopram Hbr | 13 | $73 | $6 |
2013: 1 drug
| Omeprazole | 11 | $84 | $8 |
Money from drug and device companies
$8,619 in 2025
| 2025 | 47 | 214 | $3,600 | $8,619 |
| 2024 | 44 | 192 | $525 | $5,096 |
| 2023 | 22 | 66 | $8,121 | $10,517 |
| 2022 | 12 | 32 | $6,064 | $6,735 |
| 2021 | 5 | 14 | None | $345 |
| 2020 | 16 | 51 | $12,700 | $14,979 |
| 2019 | 37 | 342 | $52,684 | $67,742 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Elahere | $3,650 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $1,014 | 24 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $330 | 14 payments
|
| Pfizer | Ibrance | $247 | 7 payments
|
| Janssen Biotech | Erleada | $210 | 10 payments
|
| Sobi | Vonjo | $199 | 9 payments
|
See all 200 published payments
| GlaxoSmithKline | Meals · 2025-12-22 | Ojjaara | $0 |
| GlaxoSmithKline | Meals · 2025-12-19 | Ojjaara | $16 |
| Aveo Pharmaceuticals | Meals · 2025-12-16 | Fotivda | $10 |
| Exelixis | Meals · 2025-12-15 | Cabometyx | $33 |
| Sobi | Meals · 2025-12-15 | Vonjo | $24 |
| Puma Biotechnology | Meals · 2025-12-10 | Nerlynx | $27 |
| Caris MPI | Meals · 2025-12-09 | Mi Cancer Seek | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-08 | Enhertu | $24 |
| Adc Therapeutics America | Meals · 2025-12-06 | Zynlonta | $18 |
| PharmaEssentia USA | Meals · 2025-12-05 | Besremi | $21 |
| Daiichi Sankyo | Meals · 2025-12-03 | Enhertu | $19 |
| Daiichi Sankyo | Meals · 2025-12-03 | Enhertu | $4 |
| Daiichi Sankyo | Meals · 2025-12-02 | Enhertu | $2 |
| Novartis Pharmaceuticals | Meals · 2025-12-02 | Pluvicto | $35 |
| Caris MPI | Meals · 2025-12-02 | Mi Cancer Seek | $20 |
| Verity Pharmaceuticals | Meals · 2025-11-24 | Trelstar | $14 |
| Sobi | Meals · 2025-11-24 | Vonjo | $23 |
| Janssen Biotech | Meals · 2025-11-18 | Erleada | $24 |
| Alexion Pharmaceuticals | Meals · 2025-11-18 | Ultomiris | $31 |
| Ipsen Biopharmaceuticals | Meals · 2025-11-13 | Onivyde | $23 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Kisqali | $22 |
| Astellas Pharma US | Meals · 2025-11-08 | Vyloy | $34 |
| Exelixis | Meals · 2025-11-06 | Cabometyx | $27 |
| Pfizer | Meals · 2025-11-04 | Elrexfio | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-03 | Fabhalta | $15 |
| Merck Sharp & Dohme | Meals · 2025-10-28 | Keytruda | $23 |
| Daiichi Sankyo | Meals · 2025-10-27 | Datroway | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-25 | Enhertu | $23 |
| Caris MPI | Meals · 2025-10-22 | Mi Cancer Seek | $22 |
| Janssen Biotech | Meals · 2025-10-21 | Darzalex | $13 |
| Aveo Pharmaceuticals | Meals · 2025-10-21 | Fotivda | $16 |
| Aveo Pharmaceuticals | Education · 2025-10-20 | Fotivda | $93 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Kisqali | $33 |
| Array Biopharma | Meals · 2025-10-14 | Lorbrena | $22 |
| Lilly USA | Meals · 2025-10-08 | Verzenio | $20 |
| Exelixis | Meals · 2025-10-07 | Cabometyx | $25 |
| Octapharma USA | Meals · 2025-10-07 | Octagam Immune Globulin (Human) | $29 |
| Agios Pharmaceuticals | Meals · 2025-10-03 | Pyrukynd | $27 |
| Genentech USA | Meals · 2025-10-02 | Polivy | $15 |
| Genzyme | Meals · 2025-09-30 | Wayrilz | $25 |
| Sobi | Meals · 2025-09-30 | Vonjo | $26 |
| Abbvie | Meals · 2025-09-26 | Elahere | $28 |
| Alexion Pharmaceuticals | Meals · 2025-09-25 | Ultomiris | $33 |
| Janssen Biotech | Meals · 2025-09-24 | Talvey | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-24 | Scemblix | $23 |
| GlaxoSmithKline | Meals · 2025-09-23 | Ojjaara | $4 |
| Puma Biotechnology | Meals · 2025-09-22 | Nerlynx | $27 |
| Astellas Pharma US | Meals · 2025-09-21 | Vyloy | $1 |
| Astellas Pharma US | Meals · 2025-09-20 | Vyloy | $32 |
| GlaxoSmithKline | Meals · 2025-09-18 | Ojjaara | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-18 | Enhertu | $30 |
| SpringWorks Therapeutics | Meals · 2025-09-17 | Ogsiveo | $16 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-16 | None | $19 |
| Lilly USA | Meals · 2025-09-09 | Verzenio | $26 |
| PharmaEssentia USA | Meals · 2025-09-08 | Besremi | $29 |
| Incyte | Meals · 2025-08-27 | Zynyz | $19 |
| Tactile Systems Technology | Meals · 2025-08-26 | Flexitouch Plus | $49 |
| Array Biopharma | Meals · 2025-08-25 | Lorbrena | $33 |
| Caris MPI | Meals · 2025-08-20 | Mi Cancer Seek | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-19 | None | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-18 | Enhertu | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-08-12 | Libtayo | $32 |
| PharmaEssentia USA | Meals · 2025-08-11 | Besremi | $18 |
| Novartis Pharmaceuticals | Meals · 2025-08-06 | Fabhalta | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Kisqali | $21 |
| Ipsen Biopharmaceuticals | Meals · 2025-08-05 | Onivyde | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-04 | Enhertu | $23 |
| Merck Sharp & Dohme | Meals · 2025-07-31 | Keytruda | $28 |
| Tempus AI | Meals · 2025-07-30 | Xt Cdx | $16 |
| GlaxoSmithKline | Meals · 2025-07-29 | Ojjaara | $12 |
| Astellas Pharma US | Meals · 2025-07-29 | Vyloy | $31 |
| Astellas Pharma US | Meals · 2025-07-29 | Vyloy | $1 |
| Exelixis | Meals · 2025-07-28 | Cabometyx | $29 |
| Stemline Therapeutics | Meals · 2025-07-24 | Orserdu | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-22 | Imfinzi | $21 |
| Daiichi Sankyo | Meals · 2025-07-21 | Datroway | $1 |
| Daiichi Sankyo | Meals · 2025-07-21 | Datroway | $8 |
| Daiichi Sankyo | Meals · 2025-07-21 | Datroway | $5 |
| Abbvie | Consulting · 2025-07-21 | None | $3,600 |
| Iovance Biotherapeutics | Meals · 2025-07-17 | Amtagvi | $28 |
| Alexion Pharmaceuticals | Meals · 2025-07-15 | Ultomiris | $35 |
| Pfizer | Meals · 2025-07-15 | Xtandi | $5 |
| Novartis Pharmaceuticals | Meals · 2025-07-14 | Pluvicto | $32 |
| SpringWorks Therapeutics | Meals · 2025-07-14 | Ogsiveo | $29 |
| GlaxoSmithKline | Meals · 2025-07-10 | Ojjaara | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-09 | Alunbrig | $27 |
| Novartis Pharmaceuticals | Meals · 2025-07-08 | Kisqali | $30 |
| Incyte | Meals · 2025-07-07 | Monjuvi | $23 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | Scemblix | $26 |
| Janssen Biotech | Meals · 2025-07-01 | Erleada | $17 |
| Novocure | Meals · 2025-07-01 | Optune Lua (Novottf-200t) | $15 |
| Array Biopharma | Meals · 2025-06-25 | Lorbrena | $19 |
| Alexion Pharmaceuticals | Meals · 2025-06-23 | Ultomiris | $29 |
| Pfizer | Meals · 2025-06-17 | Ibrance | $145 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-16 | Nubeqa | $26 |
| Janssen Biotech | Meals · 2025-06-12 | Rybrevant | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $83 |
| Amneal Pharmaceuticals | Meals · 2025-06-11 | Alymsys | $17 |
| Novartis Pharmaceuticals | Meals · 2025-06-10 | Fabhalta | $21 |
| Gilead Sciences | Meals · 2025-06-10 | Trodelvy | $30 |
| Tempus AI | Meals · 2025-06-05 | Xt Cdx | $16 |
| Aveo Pharmaceuticals | Meals · 2025-06-03 | Fotivda | $15 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-03 | None | $22 |
| Shield Therapeutics | Meals · 2025-06-03 | Accrufer | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-02 | Enhertu | $19 |
| Seagen | Education · 2025-06-01 | None | $83 |
| Sobi | Meals · 2025-05-30 | Vonjo | $19 |
| Novartis Pharmaceuticals | Meals · 2025-05-29 | Kisqali | $30 |
| Daiichi Sankyo | Meals · 2025-05-26 | Enhertu | $19 |
| Daiichi Sankyo | Meals · 2025-05-26 | Enhertu | $3 |
| Daiichi Sankyo | Meals · 2025-05-26 | Enhertu | $4 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-21 | Alunbrig | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-19 | Lynparza | $23 |
| Exelixis | Meals · 2025-05-19 | Cabometyx | $24 |
| Stemline Therapeutics | Meals · 2025-05-17 | Orserdu | $35 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $100 |
| Regeneron Healthcare Solutions | Meals · 2025-05-15 | Libtayo | $30 |
| Merck Sharp & Dohme | Meals · 2025-05-13 | Keytruda | $24 |
| Novartis Pharmaceuticals | Meals · 2025-05-12 | Scemblix | $17 |
| Array Biopharma | Meals · 2025-05-09 | Lorbrena | $3 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-08 | Enhertu | $21 |
| Genentech USA | Meals · 2025-05-08 | Polivy | $27 |
| Array Biopharma | Meals · 2025-05-08 | Lorbrena | $15 |
| Merck Sharp & Dohme | Meals · 2025-05-07 | Keytruda | $21 |
| Novartis Pharmaceuticals | Meals · 2025-05-06 | Kisqali | $23 |
| Pfizer | Meals · 2025-05-05 | Elrexfio | $16 |
| Sobi | Meals · 2025-05-05 | Vonjo | $13 |
| Sobi | Meals · 2025-05-05 | Vonjo | $19 |
| Pfizer | Meals · 2025-04-30 | Elrexfio | $24 |
| Astellas Pharma US | Meals · 2025-04-30 | Padcev | $22 |
| Aveo Pharmaceuticals | Meals · 2025-04-29 | Fotivda | $25 |
| Janssen Biotech | Meals · 2025-04-28 | Carvykti | $20 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $100 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-24 | None | $14 |
| Daiichi Sankyo | Meals · 2025-04-22 | Enhertu | $8 |
| TerSera Therapeutics | Meals · 2025-04-21 | Quzyttir | $27 |
| Eisai | Meals · 2025-04-16 | Lenvima | $25 |
| Array Biopharma | Meals · 2025-04-15 | Xalkori | $23 |
| Merck Sharp & Dohme | Meals · 2025-04-15 | Keytruda | $23 |
| Gilead Sciences | Meals · 2025-04-14 | Trodelvy | $22 |
| Pfizer | Meals · 2025-04-10 | Talzenna | $22 |
| Novartis Pharmaceuticals | Meals · 2025-04-08 | Scemblix | $10 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-07 | Enhertu | $14 |
| Daiichi Sankyo | Meals · 2025-04-03 | Enhertu | $28 |
| Daiichi Sankyo | Meals · 2025-04-02 | Enhertu | $3 |
| Daiichi Sankyo | Meals · 2025-04-02 | Enhertu | $29 |
| Verity Pharmaceuticals | Meals · 2025-03-31 | Trelstar | $33 |
| Novartis Pharmaceuticals | Meals · 2025-03-27 | Pluvicto | $32 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $100 |
| Astellas Pharma US | Meals · 2025-03-26 | Vyloy | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-25 | None | $25 |
| Astellas Pharma US | Meals · 2025-03-25 | Vyloy | $2 |
| Sobi | Meals · 2025-03-24 | Vonjo | $20 |
| Abbvie | Meals · 2025-03-21 | Elahere | $23 |
| Array Biopharma | Meals · 2025-03-21 | Braftovi | $20 |
| GlaxoSmithKline | Meals · 2025-03-20 | Ojjaara | $17 |
| Servier Pharmaceuticals | Meals · 2025-03-20 | Voranigo | $17 |
| Recordati Rare Diseases Inc. | Meals · 2025-03-18 | Sylvant | $14 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | Scemblix | $16 |
| Eisai | Meals · 2025-03-18 | Lenvima | $28 |
| SpringWorks Therapeutics | Meals · 2025-03-14 | Ogsiveo | $28 |
| Celgene | Meals · 2025-03-10 | Opdualag | $22 |
| GlaxoSmithKline | Meals · 2025-03-10 | Jemperli | $12 |
| Incyte | Meals · 2025-03-05 | Jakafi | $23 |
| Janssen Biotech | Meals · 2025-02-26 | Tecvayli | $21 |
| Janssen Biotech | Meals · 2025-02-24 | Carvykti | $26 |
| Alexion Pharmaceuticals | Meals · 2025-02-24 | Ultomiris | $33 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $100 |
| PharmaEssentia USA | Meals · 2025-02-21 | Besremi | $32 |
| GlaxoSmithKline | Meals · 2025-02-13 | Ojjaara | $24 |
| GlaxoSmithKline | Meals · 2025-02-13 | Ojjaara | $1 |
| Geron | Meals · 2025-02-12 | Rytelo | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-11 | Lynparza | $17 |
| Celgene | Meals · 2025-02-10 | Opdivo | $23 |
| Novartis Pharmaceuticals | Meals · 2025-02-10 | Fabhalta | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Imfinzi | $62 |
| PharmaEssentia USA | Meals · 2025-02-06 | Besremi | $30 |
| Alexion Pharmaceuticals | Meals · 2025-02-05 | Ultomiris | $31 |
| Pfizer | Meals · 2025-02-03 | Elrexfio | $21 |
| Astellas Pharma US | Meals · 2025-02-02 | Vyloy | $18 |
| Astellas Pharma US | Meals · 2025-02-02 | Vyloy | $1 |
| Janssen Biotech | Meals · 2025-01-29 | Erleada | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-28 | None | $14 |
| Sobi | Meals · 2025-01-28 | Vonjo | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-27 | Opdualag | $19 |
| Incyte | Meals · 2025-01-27 | Monjuvi | $26 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $100 |
| TerSera Therapeutics | Meals · 2025-01-22 | Zoladex | $39 |
| Octapharma USA | Meals · 2025-01-17 | Octagam Immune Globulin (Human) | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Enhertu | $24 |
| Merck Sharp & Dohme | Meals · 2025-01-14 | Keytruda | $11 |
| Merck Sharp & Dohme | Meals · 2025-01-13 | Keytruda | $24 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-09 | Onivyde | $27 |
| Exelixis | Meals · 2025-01-08 | Cabometyx | $17 |
| Janssen Biotech | Meals · 2025-01-07 | Talvey | $22 |
| GlaxoSmithKline | Meals · 2025-01-07 | Jemperli | $33 |
| Array Biopharma | Meals · 2025-01-07 | Xalkori | $17 |
| Celgene | Meals · 2025-01-06 | Reblozyl | $23 |
| Sobi | Meals · 2025-01-06 | Doptelet | $28 |
| Stemline Therapeutics | Meals · 2025-01-02 | Orserdu | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,096
| AstraZeneca Pharmaceuticals LP | Imfinzi | $861 | 15 payments
|
| Novartis Pharmaceuticals | Kisqali | $860 | 20 payments
|
| Pfizer | Bosulif | $243 | 12 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $219 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $211 | 15 payments
|
| Merck Sharp & Dohme | Keytruda | $202 | 10 payments
|
| GlaxoSmithKline | Jemperli | $198 | 10 payments
|
| Daiichi Sankyo | Enhertu | $184 | 11 payments
|
| Janssen Biotech | Carvykti | $171 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $150 | 11 payments
|
| Astellas Pharma US | Xospata | $137 | 6 payments
|
| Novo Nordisk | None | $125 | 1 payment
|
| Exelixis | Cabometyx | $120 | 4 payments
|
| Abbvie | Elahere | $93 | 4 payments
|
| Lilly USA | Verzenio | $88 | 4 payments
|
| Incyte | None | $84 | 1 payment
|
| Eisai | Lenvima | $75 | 3 payments
|
| Regeneron Healthcare Solutions | Libtayo | $74 | 2 payments
|
| Genentech USA | Tecentriq | $68 | 3 payments
|
| Celgene | Reblozyl | $66 | 4 payments
|
| BeiGene USA | Brukinsa | $66 | 4 payments
|
| Array Biopharma | Braftovi | $62 | 3 payments
|
| Gilead Sciences | None | $55 | 2 payments
|
| Stemline Therapeutics | Orserdu | $49 | 1 payment
|
| Taiho Oncology | Lonsurf | $48 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $47 | 2 payments
|
| Sumitomo Pharma America | Orgovyx | $40 | 2 payments
|
| Apellis Pharmaceuticals | Empaveli | $38 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $38 | 2 payments
|
| PharmaEssentia USA | Besremi | $37 | 2 payments
|
| Myriad Genetic Laboratories | Myrisk | $37 | 1 payment
|
| Octapharma USA | Octagam Immune Globulin (Human) | $35 | 2 payments
|
| Medtronic | Osteocool Rf Ablation System | $35 | 1 payment
|
| Immunocore | Kimmtrak | $34 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $33 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $26 | 1 payment
|
| Tempus AI | None | $25 | 1 payment
|
| Geron | Rytelo | $25 | 1 payment
|
| Accord Healthcare | Camcevi | $24 | 1 payment
|
| Servier Pharmaceuticals | Voranigo | $24 | 1 payment
|
| Genzyme | Sarclisa | $24 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $24 | 1 payment
|
| BioMarin Pharmaceutical | Roctavian | $23 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $20 | 1 payment
|
2023: $10,517
| E.R. Squibb & Sons L.L.C. | Opdivo | $8,080 | 25 payments
|
| Pfizer | Ibrance | $1,402 | 3 payments
|
| Daiichi Sankyo | Enhertu | $385 | 2 payments
|
| Novartis Pharmaceuticals | Scemblix | $129 | 13 payments
|
| GlaxoSmithKline | Zejula | $66 | 3 payments
|
| Janssen Biotech | Erleada | $43 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $34 | 1 payment
|
| Exelixis | Cabometyx | $33 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $32 | 2 payments
|
| Genentech USA | Tecentriq | $31 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $28 | 1 payment
|
| Sobi | Doptelet | $28 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $28 | 1 payment
|
| Incyte | Monjuvi | $27 | 1 payment
|
| Amgen | Lumakras | $26 | 1 payment
|
| Lilly USA | Verzenio | $26 | 1 payment
|
| Astellas Pharma US | Xtandi | $24 | 1 payment
|
| PharmaEssentia USA | Besremi | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $20 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $19 | 1 payment
|
| Celgene | Reblozyl | $18 | 1 payment
|
| ImmunoGen | Elahere | $17 | 1 payment
|
2022: $6,735
| E.R. Squibb & Sons L.L.C. | Opdivo | $3,167 | 16 payments
|
| Celgene | None | $3,000 | 2 payments
|
| Incyte | Jakafi | $149 | 2 payments
|
| Lilly USA | None | $108 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $85 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $72 | 4 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $45 | 1 payment
|
| Janssen Biotech | Rybrevant | $35 | 1 payment
|
| Amgen | Lumakras | $25 | 1 payment
|
| GlaxoSmithKline | Zejula | $20 | 1 payment
|
| Daiichi Sankyo | Injectafer | $17 | 1 payment
|
| Pfizer | Bosulif | $12 | 1 payment
|
2021: $345
| Lilly USA | None | $154 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $125 | 9 payments
|
| GlaxoSmithKline | Blenrep | $29 | 1 payment
|
| AbbVie | Creon | $18 | 1 payment
|
| Kyowa Kirin | Sancuso | $18 | 1 payment
|
2020: $14,979
| Amgen | Vectibix | $12,324 | 13 payments
|
| GlaxoSmithKline | Zejula | $1,973 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $354 | 16 payments
|
| Novartis Pharmaceuticals | Votrient | $65 | 4 payments
|
| Pfizer | Xtandi | $48 | 3 payments
|
| Genzyme | Elitek | $47 | 2 payments
|
| Eisai | Lenvima | $23 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $20 | 1 payment
|
| Astellas Pharma US | Xospata | $19 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $18 | 1 payment
|
| Genentech USA | Tecentriq | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $17 | 1 payment
|
| Seagen | Padcev | $15 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $13 | 1 payment
|
| Exelixis | Cabometyx | $13 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Vonvendi | $11 | 1 payment
|
2019: $67,742
| Amgen | Vectibix | $42,291 | 61 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $15,472 | 75 payments
|
| Eli Lilly and | Cyramza | $5,187 | 21 payments
|
| Bayer HealthCare Pharmaceuticals | Aliqopa | $998 | 5 payments
|
| Genzyme | Jevtana | $861 | 4 payments
|
| Pfizer | Xalkori | $331 | 32 payments
|
| Novartis Pharmaceuticals | Tasigna | $311 | 21 payments
|
| Astellas Pharma US | Xtandi | $259 | 6 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $249 | 6 payments
|
| Janssen Biotech | Erleada | $226 | 26 payments
|
| Tesaro | Zejula | $152 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $139 | 9 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $134 | 4 payments
|
| AbbVie | Venclexta | $123 | 9 payments
|
| Exelixis | Cabometyx | $122 | 8 payments
|
| Lilly USA | Verzenio | $121 | 3 payments
|
| Genentech USA | Tecentriq | $119 | 14 payments
|
| Seattle Genetics | None | $118 | 3 payments
|
| TerSera Therapeutics | Varubi | $78 | 4 payments
|
| Eisai | Lenvima | $61 | 4 payments
|
| Dova Pharmaceuticals | Doptelet | $58 | 3 payments
|
| Gilead Sciences | None | $45 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $38 | 3 payments
|
| Daiichi Sankyo | Injectafer | $33 | 2 payments
|
| Shire North American Group | Obizur | $23 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $20 | 1 payment
|
| Lexicon Pharmaceuticals | Xermelo | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $18 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $17 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $16 | 1 payment
|
| Celgene | Pomalyst | $15 | 1 payment
|
| Kyowa Kirin | Poteligeo | $14 | 1 payment
|
| Puma Biotechnology | Nerlynx | $13 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $13 | 1 payment
|
| Incyte | Jakafi | $13 | 1 payment
|
| Stemline Therapeutics | Elzonris | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim Pharmaceuticals, Inc. · Beamion Lung-2: A Phase III, Open-Label, Randomised, Active-Controlled, Multi-Centre Trial Evaluating Orally Administered Bi 1810631 Compared To Standard of Care As First-Line Treatment in Patients With Unresectable, Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer Harbouring Her2 Tyrosine Kinase Domain Mutations · 2025 | Their institution | $39,805 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Beamion Lung-2: A Phase III, Open-Label, Randomised, Active-Controlled, Multi-Centre Trial Evaluating Orally Administered Bi 1810631 Compared To Standard of Care As First-Line Treatment in Patients With Unresectable, Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer Harbouring Her2 Tyrosine Kinase Domain Mutations · 2025 | Their institution | $2,558 |
| Boehringer Ingelheim International GmbH · Beamion Lung-3: A Randomized, Controlled, Multi-Center Trial Evaluating Zongertinib As An Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-Stage, Resectable Non-Small Cell Lung Cancer (Stage II-Iiib) Harboring Tyrosine Kinase Domain Activating Her2 Mutations · 2025 | Their institution | $1,872 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417906835
- Licence
- CA C-144556, MI 4301091113, OH 5135086241California C144556: Current · expires 2027-09-30
- Group
- Premier Cancer Care and Infusion Center · Camarena Health
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- OH 2625574
- Taxonomy
- Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Medical oncology (207RX0202X); Hospitalist (208M00000X)
- Mailing address
- 7065 N. Maple Ave, Ste 102, Fresno, CA, 93720
- NPI first listed
- 2006-05-10
- NPI last updated
- 2024-01-12
- NPI record certified
- 2024-01-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 7130 N Millbrook Ave, Fresno, CA, 93720